Literature DB >> 8263850

Systemic toxicity associated with doxorubicin administration in cats.

D A O'Keefe1, D D Sisson, H B Gelberg, D J Schaeffer, D R Krawiec.   

Abstract

The systemic toxicity of doxorubicin, 30 mg/m2 body surface area (BSA) every 21 days to a cumulative dose of 300 mg/m2, was evaluated in six cats. Appetite, body weight, and the presence of vomiting and/or diarrhea were monitored throughout the study. Renal function was monitored by measuring serum blood urea nitrogen (BUN) and creatinine concentrations, urine specific gravity, and creatinine clearance before each treatment. Electrocardiograms and echocardiograms were also done before each treatment. The cats were killed 3 weeks after the last treatment, and complete necropsies were performed. Partial or complete anorexia occurred in all cats with significant weight loss occurring after a cumulative doxorubicin dose of 150 mg/m2 BSA. Mild vomiting and diarrhea that required no treatment also occurred sporadically in all cats. Echocardiographic changes consistent with doxorubicin-induced cardiomyopathy occurred in four cats after cumulative doses of 170 to 240 mg/m2 BSA. Clinical heart disease and electrocardiographic changes were not observed. Subsequent histological examination revealed myocyte vacuolization and myocytolysis in all six hearts. Renal dysfunction, characterized by increasing azotemia with progressively more dilute urine, was detected in two cats. Mean creatinine clearance values also decreased significantly throughout the study. At necropsy, all cats had histological evidence of renal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263850     DOI: 10.1111/j.1939-1676.1993.tb01024.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  7 in total

1.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

2.  Hematological and clinical responses to combined mitoxantrone and cyclophosphamide administration to normal cats.

Authors:  C J Henry; W G Brewer; N S Royer
Journal:  Can Vet J       Date:  1994-11       Impact factor: 1.008

3.  Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas.

Authors:  Yike Bing; Zacharie Wund; Tina Abratte; Lucia Borlle; Susie Kang; Teresa Southard; Kelly R Hume
Journal:  Cancer Cell Int       Date:  2018-11-22       Impact factor: 5.722

4.  Cloning and expression of feline colony stimulating factor receptor (CSF-1R) and analysis of the species specificity of stimulation by colony stimulating factor-1 (CSF-1) and interleukin-34 (IL-34).

Authors:  Deborah J Gow; Valerie Garceau; Clare Pridans; Adam G Gow; Kerry E Simpson; Danielle Gunn-Moore; David A Hume
Journal:  Cytokine       Date:  2012-12-19       Impact factor: 3.861

5.  Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Authors:  Kevin Marley; Stuart C Helfand; Jennifer Simpson; John E Mata; William G Tracewell; Lisa Brownlee; Shay Bracha; Bernard Séguin
Journal:  J Exp Clin Cancer Res       Date:  2013-10-11

6.  Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin.

Authors:  Lucy Kopecny; Carrie A Palm; Katherine A Skorupski; Mikel Delgado; Robert B Rebhun
Journal:  J Vet Intern Med       Date:  2020-08-11       Impact factor: 3.333

7.  Evaluation of TFR-1 Expression in Feline Mammary Cancer and In Vitro Antitumor Efficacy Study of Doxorubicin-Loaded H-Ferritin Nanocages.

Authors:  Nicolò Rensi; Alessandro Sammarco; Valentina Moccia; Alessandro Calore; Filippo Torrigiani; Davide Prosperi; Maria Antonietta Rizzuto; Michela Bellini; Raffaella De Maria; Federico Bonsembiante; Silvia Ferro; Rossella Zanetti; Valentina Zappulli; Laura Cavicchioli
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.